# Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

> **NCT05891483** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 114 (actual)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** SHR-1905 Injection
- **DRUG:** SHR-1905 Placebo Injection

## Key facts

- **NCT ID:** NCT05891483
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-04
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891483, "Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05891483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*